...
首页> 外文期刊>Xenobiotica: the fate of foreign compounds in biological systems >Application of structure-metabolism relationships in the identification of a selective endothelin A antagonist, BMS-193884, with favourable pharmacokinetic properties.
【24h】

Application of structure-metabolism relationships in the identification of a selective endothelin A antagonist, BMS-193884, with favourable pharmacokinetic properties.

机译:结构代谢关系在鉴定具有良好药代动力学特性的选择性内皮素A拮抗剂BMS-193884中的应用。

获取原文
获取原文并翻译 | 示例
           

摘要

1. Based on binding affinity, 2'-amino-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,1'-biphenyl]- 2-sulfonamide (2) was identified as an initial lead in a programme to identify selective endothelin (ET) receptor antagonists. However, the compound was extensively metabolized in preclinical animal species and human in vitro systems due to oxidative biotransformation. 2. To optimize this structural class, the site of metabolism of 2 was determined. This allowed for focussed structure-activity and structure-metabolism studies aimed at finding more metabolically stable analogues that maintained potency. New analogues were screened for their ET binding characteristics and their stability in rat and human liver microsomes. 3. The use of the microsomal stability screen was tested by the determination of the pharmacokinetic parameters of select analogues. A good correlation was found between reduced rates of rat microsomal metabolism and reduced clearance in the rat. 4. N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide (3) was identified as an analogue with improved in vitro properties and further studies revealed that the compound had improved pharmacokinetic properties. 5. N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-bi phenyl]-2-yl]methyl]acetamide (4) was subsequently identified as a compound with superior in vitro properties compared with compound 3, but when tested in vivo it had a substantially increased rate of clearance. Further studies demonstrated that the clearance of this closely related structural analogue was not dictated by metabolic processes, but was mediated by transport-mediated direct biliary excretion. 6. The utility of screening for in vitro liver microsomal stability as part of the lead optimization process for compounds with metabolic liabilities was shown. It was also shown that relatively small molecular changes can dramatically change the disposition of closely related analogues and care must be used when screening for a single property.
机译:1.基于结合亲和力,得到2'-氨基-N-(3,4-二甲基-5-异恶唑基)-4'-(2-甲基丙基)[1,1'-联苯基] -2-磺酰胺(2)。在鉴定选择性内皮素(ET)受体拮抗剂的计划中被确定为最初牵头人。但是,由于氧化生物转化,该化合物在临床前动物物种和人体体外系统中广泛代谢。 2.为了优化该结构类别,确定了2的代谢位点。这使得集中的结构-活性和结构-代谢研究旨在寻找保持效能的代谢稳定的类似物。筛选新的类似物的ET结合特性及其在大鼠和人肝微粒体中的稳定性。 3.通过确定所选类似物的药代动力学参数来测试微粒体稳定性筛选的使用。在大鼠微粒体代谢率降低与大鼠清除率降低之间发现了良好的相关性。 4. N-(3,4-二甲基-5-异恶唑基)-4'-(2-恶唑基)[1,1'-联苯] -2-磺酰胺(3)被鉴定为具有改进的体外特性的类似物,并且进一步的研究表明该化合物具有改善的药代动力学特性。 5. N-[[2'-[[((3,4-二甲基-5-异恶唑基)氨基]磺酰基] -4-(2-恶唑基)[1,1'-联苯基] -2-基]甲基]乙酰胺(4)随后被鉴定为具有比化合物3更好的体外特性的化合物,但是在体内测试时,其清除率大大提高。进一步的研究表明,这种密切相关的结构类似物的清除不是由代谢过程决定的,而是由转运介导的直接胆汁排泄介导的。 6.显示了对体外肝微粒体稳定性进行筛选的实用性,作为筛选具有代谢功能的化合物的最优化方法的一部分。研究还表明,相对较小的分子变化可以显着改变密切相关的类似物的结构,在筛选单一特性时必须小心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号